My Size, Inc. (NASDAQ: MYSZ) Measuring App in the Spotlight Following Partnership with Fashion Retailer Trucco
One of the biggest problems facing ecommerce – online fashion retailers, in particular – is high return rates due to…
Blog
Singlepoint, Inc. (SING) Kicks Off 2017 by Voicing Support for Congressional Push Calling for Banking Reform in the Cannabis Industry
Before the opening bell, Singlepoint, Inc. (OTC: SING) kicked off the new year by voicing its support for an ongoing…
PixarBio Corporation (PXRB) Takes the Addiction out of Painkillers with NeuroRelease™
Remedies for pain have progressed beyond the one recommended in Shakespeare’s Romeo and Juliet, where the renowned playwright wrote, "One…
FTE Networks, Inc. (FTNW) is Enabling the Connection
In less than a decade, we’ve seen multiple networks spring up that are now connecting hundreds of millions of people.…
At National Waste Management Holdings, Inc. (NWMH), Diverse Revenue Streams lead to Healthy Cash Flow
With close to half a million sitting in the bank and in short-term securities at the end of the third…
Biotricity, Inc. (BTCY) – A Modern Technology Company for Medical and Consumer Markets
Modern technological advancements are permeating all facets of society and industry and encouraging remote interactions from anywhere and at anytime.…
CytoDyn Inc. (CYDY) Announces Engagement of NetworkNewsWire for Corporate Communications Solutions
CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus…
QualityStocks Keeps Investors Abreast of Small-cap Market’s Latest and Greatest
There’s a barrage of financial information available at any given moment – while it initially sounds great, investors need a…
OurPet’s Company (OPCO), Growing 50% Faster than the Industry Rate, Is a Bargain Buy
In the world of value investing, not all that is gold glitters… like Ohio-based OurPet’s Company, for example. OurPet’s Company…
CytoDyn Inc. (CYDY) Targets HIV as its Lead Product, PRO 140, Enters Phase 3 Clinical Development
CytoDyn Inc. (OTCQB: CYDY) is entering a Phase 3 clinical trial with its leading product candidate, PRO 140, and the…